Dostarlimab

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

Tuesday, May 4, 2021 - 9:05pm

We also commenced an imsidolimab Phase 2 trial in moderate-to-severe acne, named ACORN, where 120-patients are randomized equally between two dose levels of imsidolimab and placebo, and top-line data is anticipated in H1 2022.

Key Points: 
  • We also commenced an imsidolimab Phase 2 trial in moderate-to-severe acne, named ACORN, where 120-patients are randomized equally between two dose levels of imsidolimab and placebo, and top-line data is anticipated in H1 2022.
  • This is the first AnaptysBio-generated antibody, of eight currently under clinical development, to obtain FDA approval.
  • We earned a $10.0 million milestone payment as a result of this approval.\nA second BLA submitted by GSK was accepted by the FDA during the first quarter of 2021 for JEMPERLI in pan-deficient mismatch repair tumors (PdMMRT).
  • Statements including words such as \xe2\x80\x9cplan,\xe2\x80\x9d \xe2\x80\x9ccontinue,\xe2\x80\x9d \xe2\x80\x9cexpect,\xe2\x80\x9d or \xe2\x80\x9congoing\xe2\x80\x9d and statements in the future tense are forward-looking statements.